By Infinium Global Research Aug, 2020
The glycated hemoglobin is the one form of hemoglobin that used to measured average plasma glucose concentration. The glycated hemoglobin testing is a measured amount of glycosylated hemoglobin in the blood. Glycated hemoglobin test shows the blood glucose levels over the past six to eight weeks and helps to determine how diabetes is being controlled over time. The rapidly growing occurrence of diabetes across the globe drives the growth of the glycated hemoglobin test market. According to the WHO, 422 million adults have been diagnosed with diabetes globally and it has been steadily increasing in the low level and middle-level people. Diabetes is one of the leading causes of death in the world so they need effective and accurate tests to determine and control diabetes are rising very rapidly. The rising geriatric population and growing awareness about diabetes are contributing to the growth of the glycated hemoglobin market. However, high costs associated with glycated hemoglobin testing devices are hampering the growth of the glycated hemoglobin testing market. Moreover, technological advancements in monitoring technologies and devices and the growing geriatric population are projected to create several opportunities in the glycated hemoglobin test market.
The report on global glycated hemoglobin testing market covers segments such as type, technique, and end-user. The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the world In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The report provides profiles of the companies in the global Abbott Laboratories Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Roche Holdings AG, Randox Laboratories Ltd., Siemens AG, Sebia SA, A. Menarini Diagnostics Ltd., and Trinity Biotech Inc.